Travere Therapeutics IncTVTX
Price$58.88

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $591.3M+153.6% YoYTTM through 30 Jun 2026
Net Income -$43.5MTTM through 30 Jun 2026
Free Cash Flow $39.6MTTM through 30 Jun 2026

Margins

Current
EBITDA Margin3.9%
Operating Margin-6.8%
Net Margin-7.4%

Returns

-177.2%ROE
-5.4%ROA

Balance Sheet Health

Debt / Equity12.71x
Current Ratio4.05x
Net Debt$47.4M
Cash & Equivalents$117.7M

Quality Metrics

Altman Z-Score2.90
Piotroski F-Score5 / 9
FCF Margin6.7%
Rule of 4028.7
Earnings-Beat Rate75.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $490.7M
Diluted EPS-$0.46TTM
'19'20'21'22'23'24'25
FY2025: $-0.29

Dividend

No dividend
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.